Genmab A/S GNMSF Stock
Genmab A/S Price Chart
Genmab A/S GNMSF Financial and Trading Overview
| Genmab A/S stock price | 343 USD |
| Previous Close | 338.98 USD |
| Open | 341 USD |
| Bid | 336.51 USD x 200 |
| Ask | 345 USD x 6100 |
| Day's Range | 341 - 341 USD |
| 52 Week Range | 232.34 - 352 USD |
| Volume | 215 USD |
| Avg. Volume | 850 USD |
| Market Cap | 20.97B USD |
| Beta (5Y Monthly) | 0.699 |
| PE Ratio (TTM) | 26.977848 |
| EPS (TTM) | 12.65 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GNMSF Valuation Measures
| Enterprise Value | 24.12B USD |
| Trailing P/E | 26.977848 |
| Forward P/E | 24.674385 |
| PEG Ratio (5 yr expected) | 5.5 |
| Price/Sales (ttm) | 5.0758114 |
| Price/Book (mrq) | 3.4175186 |
| Enterprise Value/Revenue | 5.839 |
| Enterprise Value/EBITDA | 17.517 |
Trading Information
Genmab A/S Stock Price History
| Beta (5Y Monthly) | 0.699 |
| 52-Week Change | 25.22% |
| S&P500 52-Week Change | 13.86% |
| 52 Week High | 352 USD |
| 52 Week Low | 232.34 USD |
| 50-Day Moving Average | 308.6 USD |
| 200-Day Moving Average | 293.66 USD |
GNMSF Share Statistics
| Avg. Volume (3 month) | 850 USD |
| Avg. Daily Volume (10-Days) | 100 USD |
| Shares Outstanding | 61.49M |
| Float | 58.96M |
| Short Ratio | N/A |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 41.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 19.07% |
| Operating Margin (ttm) | 35.23% |
| Gross Margin | 93.02% |
| EBITDA Margin | 33.33% |
Management Effectiveness
| Return on Assets (ttm) | 8.78% |
| Return on Equity (ttm) | 13.99% |
Income Statement
| Revenue (ttm) | 4.13B USD |
| Revenue Per Share (ttm) | 67.06 USD |
| Quarterly Revenue Growth (yoy) | 24.89% |
| Gross Profit (ttm) | 3.84B USD |
| EBITDA | 1.38B USD |
| Net Income Avi to Common (ttm) | 788M USD |
| Diluted EPS (ttm) | 12.64 |
| Quarterly Earnings Growth (yoy) | -9.80% |
Balance Sheet
| Total Cash (mrq) | 1.51B USD |
| Total Cash Per Share (mrq) | 25.29 USD |
| Total Debt (mrq) | 5.27B USD |
| Total Debt/Equity (mrq) | 88.52 USD |
| Current Ratio (mrq) | 2.457 |
| Book Value Per Share (mrq) | 99.78 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 891M USD |
| Levered Free Cash Flow (ttm) | 870.63M USD |
Profile of Genmab A/S
| Country | United States |
| State | N/A |
| City | Copenhagen |
| Address | Carl Jacobsens Vej 30 |
| ZIP | 2500 |
| Phone | 45 70 20 27 28 |
| Website | https://www.genmab.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3119 |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Q&A For Genmab A/S Stock
What is a current GNMSF stock price?
Genmab A/S GNMSF stock price today per share is 343 USD.
How to purchase Genmab A/S stock?
You can buy GNMSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genmab A/S?
The stock symbol or ticker of Genmab A/S is GNMSF.
Which industry does the Genmab A/S company belong to?
The Genmab A/S industry is Biotechnology.
How many shares does Genmab A/S have in circulation?
The max supply of Genmab A/S shares is 61.49M.
What is Genmab A/S Price to Earnings Ratio (PE Ratio)?
Genmab A/S PE Ratio is 27.11462600 now.
What was Genmab A/S earnings per share over the trailing 12 months (TTM)?
Genmab A/S EPS is 12.65 USD over the trailing 12 months.
Which sector does the Genmab A/S company belong to?
The Genmab A/S sector is Healthcare.
